286 related articles for article (PubMed ID: 31099691)
1. Updates in Local-Regionally Advanced Non-Small Cell Lung Cancer.
Tsao AS; Jolly S; Lee JM
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():553-562. PubMed ID: 31099691
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?
Buffoni L; Vavalà T; Novello S
Curr Treat Options Oncol; 2016 Oct; 17(10):54. PubMed ID: 27523606
[TBL] [Abstract][Full Text] [Related]
3. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
Rajappa S; Sharma S; Prasad K
Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
[TBL] [Abstract][Full Text] [Related]
4. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
Ettinger DS; Wood DE; Aisner DL; Akerley W; Bauman J; Chirieac LR; D'Amico TA; DeCamp MM; Dilling TJ; Dobelbower M; Doebele RC; Govindan R; Gubens MA; Hennon M; Horn L; Komaki R; Lackner RP; Lanuti M; Leal TA; Leisch LJ; Lilenbaum R; Lin J; Loo BW; Martins R; Otterson GA; Reckamp K; Riely GJ; Schild SE; Shapiro TA; Stevenson J; Swanson SJ; Tauer K; Yang SC; Gregory K; Hughes M
J Natl Compr Canc Netw; 2017 Apr; 15(4):504-535. PubMed ID: 28404761
[TBL] [Abstract][Full Text] [Related]
5. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
Bunn PA
Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
[TBL] [Abstract][Full Text] [Related]
6. Combined modality treatment of non-small-cell lung cancer.
Westeel V; Depierre A
Am J Respir Med; 2003; 2(6):477-90. PubMed ID: 14719987
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.
Puri S; Shafique M; Gray JE
Curr Treat Options Oncol; 2018 Jun; 19(8):39. PubMed ID: 29931587
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced (stages III and IV) non-small-cell lung cancer.
Sweeney CJ; Sandler AB
Curr Probl Cancer; 1998; 22(2):85-132. PubMed ID: 9580849
[TBL] [Abstract][Full Text] [Related]
9. Combined modality therapy of non-small cell lung cancers.
Juretic A; Sobat H; Samija M
Ann Oncol; 1999; 10 Suppl 6():93-8. PubMed ID: 10676559
[TBL] [Abstract][Full Text] [Related]
10. The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer.
Ko EC; Raben D; Formenti SC
Clin Cancer Res; 2018 Dec; 24(23):5792-5806. PubMed ID: 29945993
[TBL] [Abstract][Full Text] [Related]
11. Oligometastatic non-small cell lung cancer: Where do we go next?
Malik N; Palma D
Lung Cancer; 2017 Apr; 106():145-147. PubMed ID: 28062090
[No Abstract] [Full Text] [Related]
12. Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer.
Choong NW; Vokes EE
Clin Lung Cancer; 2005 Dec; 7 Suppl 3():S98-104. PubMed ID: 16384544
[TBL] [Abstract][Full Text] [Related]
13. Role of chemotherapy in stages I to III non-small cell lung cancer.
Strauss GM
Chest; 1999 Dec; 116(6 Suppl):509S-516S. PubMed ID: 10619521
[TBL] [Abstract][Full Text] [Related]
14. Combined modality therapy of early stage nonsmall cell lung cancer.
Pisters KM
Respir Care Clin N Am; 2003 Jun; 9(2):191-205. PubMed ID: 12911289
[TBL] [Abstract][Full Text] [Related]
15. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
16. [Progress in Neoadjuvant Immunotherapies for Resectable Non-small Cell Lung Cancer].
Wang S; Mao Y
Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):371-380. PubMed ID: 32283581
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Therapy in Non-Small Cell Lung Cancer.
Zheng Y; Jaklitsch MT; Bueno R
Surg Oncol Clin N Am; 2016 Jul; 25(3):567-84. PubMed ID: 27261916
[TBL] [Abstract][Full Text] [Related]
18. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
19. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Ramnath N; Dilling TJ; Harris LJ; Kim AW; Michaud GC; Balekian AA; Diekemper R; Detterbeck FC; Arenberg DA
Chest; 2013 May; 143(5 Suppl):e314S-e340S. PubMed ID: 23649445
[TBL] [Abstract][Full Text] [Related]
20. Advances in the Treatment of Stage III Non-Small Cell Lung Cancer.
Myall NJ; Das M
Clin Chest Med; 2020 Jun; 41(2):211-222. PubMed ID: 32402357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
